Skip to Content


FDA/Industry Exchange Workshop on FDA Clinical Trials Statutory and Regulatory Requirements; Public Workshop

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document including its time on Public Inspection. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble


Food and Drug Administration, HHS.


Notice of public workshop.


The Food and Drug Administration (FDA) Philadelphia District, in cooperation with the Society of Clinical Research Associates, (SoCRA) is announcing a workshop on FDA clinical trial statutory and regulatory requirements. Topics for discussion include: Financial incentives and funding, pre-IND (investigational new drug application) meetings and FDA meeting process, medical device aspects of clinical research, informed consent requirements, adverse event reporting, how FDA conducts bioresearch inspections, ethics in clinical research, FDA and confidence in the conduct of clinical research, and how FDA addresses fraud in clinical research. This 2-day workshop for the clinical research community targets sponsors, monitors, clinical investigators, institutional review boards and those who interact with them for the purpose of conducting FDA regulated clinical research. The workshop will include both industry and FDA perspectives on proper conduct of clinical trials regulated by FDA.

Date and Time: The public workshop is scheduled for Wednesday, June 25, 2003, from 8:30 a.m. to 4:45 p.m. and Thursday, June 26, 2003, from 8:45 a.m. to 4:45 p.m.

Location: The public workshop will be held at the Pittsburgh Marriott Center City Hotel, 112 Washington Pl., Pittsburgh, PA 15219.

Contact: Daniel R. Tammariello, FDA, 7 Parkway Center, Suite 250, Pittsburgh, PA 15220, 412-644-3394, ext. 16, FAX: 412-644-4496, e-mail: or Marie Falcone, Industry and Small Business Representative, FDA, Room 900 U.S. Customhouse, 200 Chestnut St., Start Printed Page 31721Philadelphia, PA 19106, 215-597-2120, ext. 4003, FAX: 215-597-5798, e-mail:

Registration: Send registration information (including name, title, firm name, address, telephone, and fax number) and $460 (member) or $535 (non-member) registration fee made payable to SoCRA, P.O. Box 101, Furlong, PA 18925. To register via the Internet go to​FDA_​Conference.htm. FDA has verified the Web site address, but is not responsible for subsequent changes to the Web site after this document publishes in the Federal Register.

Registrar will also accept payment by major credit cards. For more information on the meeting, or for questions on registration, contact 800 -SoCRA92 (800-762-7292), or 215-345-7369 or via e-mail to Attendees are responsible for their own accommodations. To make reservations at the Pittsburgh Marriott Center City Hotel at the reduced conference rate, contact the Pittsburgh Marriott Center City Hotel at 412-471-4000 or 888-456-6600 or by fax at hotel FAX: 412-281-4797 before June 3, 2003.

The registration fee will be used to offset the expenses of hosting the conference, including meals, refreshments, meeting rooms, and materials. Space is limited, therefore interested parties are encouraged to register early. Limited onsite registration may be available. Please arrive early to ensure prompt registration.

If you need special accommodations due to a disability, please contact Marie Falcone at least 7 days in advance of the workshop.

End Preamble Start Supplemental Information


The “FDA Clinical Trials Statutory and Regulatory Requirements” workshop helps fulfill the Department of Health and Human Services' and FDA's important mission to protect the public health by educating researchers on proper conduct of clinical trials. FDA has made education of the research community a high priority to assure the quality of clinical data and protect research subjects.

The workshop helps to implement the objectives of section 406 of the FDA Modernization Act (21 U.S.C. 393) and the FDA Plan for Statutory Compliance, which includes working more closely with stakeholders and ensuring access to needed scientific and technical expertise. The workshop also furthers the goals of the Small Business Regulatory Enforcement Fairness Act (Public Law 104-121) by providing outreach activities by Government agencies directed to small businesses.

Start Signature

Dated: May 20, 2003.

Jeffrey Shuren,

Assistant Commissioner for Policy.

End Signature End Supplemental Information

[FR Doc. 03-13192 Filed 5-27-03; 8:45 am]